AMSBIO's ready-to-use lentivirus supernatant products are designed for gene delivery applications including stem cell research.
With the SureTiter lentiviral system, researchers can generate high-titer
lentiviral particles for all six human stem cell factors. Each factor was
fully sequencing verified and matched to the CDs in NCBI database. High
titer lentiviral particles/supernatant were produced in 293T packaging cells
in DMEM with 10% heat-inactivated FBS. They are psudotyped with VSV-G
glycoprotein-attached vector map.
Prepared using proprietary protocols to integrate a real-time fluorescence
monitoring tag in the system, each 200ul vial of AMSBIO lentivirus
supernatent contains a high titre of highly transducible lentivirus (1 x 107
IFU/ml). Each vial of lentiviral supernatent particles contains a fully
sequence verified target, ready for transduction into any mammalian cells.
the company's lentivirus supernatent products are easy and safe to use,
simply adding 50 ul into the cultured cells will provide confirmation of the
specific target's expression under a fluorescent microscope after 48–72
hours.
Founded in 1987, AMS Biotechnology (AMSBIO) is recognised as a leading
international provider of unique & innovative products & custom
services for life sciences research. The AMSBIO range includes over 23,000
polyclonal & monoclonal antibodies, peptides, recombinant proteins,
extracellular matrix, molecular detection reagents, & tissue DNA, RNA,
protein & microarray products. Key research areas include: apoptosis,
cell invasion & migration, cell signaling, DNA damage, electrophoresis,
glycobiology, posttranslational modification & stem cell biology.